Epidemiological and Clinical Features of 156 Cases of COVID-19: A Prospective Study in Algerian Population

A B S T R A C T

Background: COVID-19 is an emerging disease caused by SARS-CoV-2. It has caused millions of infected cases and thousands of deaths since January 2020. In Algeria, the situation seems less alarming with 58,272 confirmed cases and 1,973 deaths as of November 1, 2020.
Aim of Study: To describe the clinical, biological and radiological profiles of our patients with COVID-19 during the first two months of the epidemic.
Methods: Our study is prospective over two months (April 12-June 10, 2020) including 156 patients based on clinical, radiological and/or immunological criteria.
Results: The study involved 77 men and 79 women with COVID-19 having a mean age of 48.97 ± 14.350 years. Common symptoms included asthenia (54.5%), anorexia (26.9%), fever (19.9%) and dry cough (52.6%). Biological inflammatory syndrome occurred in 32% of patients and Lymphopenia in 46%. Chest computed tomographic scans showed minimal to moderate lesions in 85.9% of cases. 56% of patients present at least one comorbidity: diabetes (25.6%), arterial hypertension (23.7%), obesity (21%), asthma (3.1%) and cancer (1.9%). The rapid serology test was positive in only 29% of 76 patients tested while Rt-PCR was positive in 35 of 55 patients tested. Length of hospital stay was 10 days for a half of patients while the rest received outpatient care. All patients were treated with hydroxychloroquine, azithromycin and preventive heparin and were followed closely until the end of treatment. The use of another antibiotic or corticosteroid was rare (3.8% and 1.3% respectively). Only one death was recorded and no transfer to an intensive care unit.
Conclusion: Our study showed that the situation was not very worrying in our population during the first two months of the epidemic. A very close surveillance of new infected cases and the analysis of their clinical profile during the following months are the subject of work in progress.

Keywords

COVID-19, epidemic, hydroxychloroquine

Introduction

In December 2019, the first cases of unexplained pneumonia were reported in Wuhan, China, caused by a novel coronavirus [1, 2]. This virus was temporarily named Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2). The disease caused by this virus, later named COVID-19 by the World Health Organization (WHO), quickly spread in China and around the world causing on November 1, 2020 more than one million deaths and 46 million infected cases [3, 4]. The spread of this disease affected Algeria in February 2020, causing, eight months later, more than 58,000 confirmed cases and 1,900 deaths [5]. Little is known about the data on the clinical profile of Algerian patients. The objective of the present study was to describe the clinical, biological and radiological profiles of our patients with COVID-19 during the first two months of the epidemic.

Method

I Study Design and Participants

We carried out a descriptive and prospective study at the El Biar Hospital of Algiers University. From April 11 to June 10 2020, we enrolled 156 patients. Only adults with a diagnosis of COVID-19 confirmed by serology test (IgM, IgG) and/or by RT-PCR (Reverse transcription polymerase chain reaction) and/or radiological signs on chest CT compatible with the disease were included in the study. We did not take care of children and pregnant women.

II Clinical Data

Demographic information, medical history, exposure history, comorbidities (diabetes, hypertension, obesity, respiratory diseases and cancer) and symptoms (asthenia, dyspnea, cough, chest pains, digestive disorders, etc.) were collected by a pre-established questionnaire. The body mass index (BMI) was measured using the formula BMI = weight (kg)/height2 (cm) and the results were interpreted according to the IDF definition: A BMI of 20-24.9 kg/m2 was considered normal, a BMI of 25-29.9 kg/m2 as overweight and a BMI ≥ 30 kg/m2 as obese [6]. Blood pressure figures were classified according to ESC 2018 [7]. Temperature, respiratory rate, heart rate and oxygen saturation were also measured. An electrocardiogram (ECG) was performed in all patients on inclusion and then every two days until the end of treatment with hydroxychloroquine to detect any prolonged QT interval [8].

III Laboratory Testing

Medical laboratory finding results, including blood cell counts (white blood cell, lymphocyte and Platelet count), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), liver test (Alanine Aminotransferase [ALAT] and Aspartate aminotransferase [ASAT]), creatinine, natremia and kalemia were collected for each patient. COVID-19 IgG/IgM Rapid Test was used for the qualitative detection of IgG and IgM antibodies to COVID-19 in whole blood, serum or plasma as an aid in the diagnosis of primary and secondary infections while nasopharyngeal samples made the molecular diagnosis by highlighting the genomic material of SARS-CoV-2 by real-time RT-PCR at Pasteur Institute of Algiers [9].

IV Computed Tomography (CT) Data

The Chest CT identified images compatible with COVID-19 pneumonia: peripheral multifocal frosted glass opacities, parenchymal condensation or mosaic appearance [10]. Based on the extent of lung lesions, radiological damage was classified into minimal (<10%), mild (10-25%), moderate (25-50%) and severe (50-70%).

V Support Protocol

All patients were treated with the combination of hydroxychloroquine (600mg/day), azithromycin (500mg on first day then 250mg/day until the fifth day) and a preventive dose of heparin (Enoxaparin) according to the national protocol for the fight against COVID-19 [11]. A cephalosporin (Cefotaxime) was prescribed for any bacterial infection and corticosteroid therapy (80mg/day of methylprednisolone) of short duration if respiratory complications. A biological monitoring workup and an ECG (calculation of the QT interval) were performed on the third, seventh and tenth days of treatment.

VI Statistical Analysis

Categorical variables were described as frequency rates and percentages and continuous variables were described using mean, median, and interquartile range. Proportions for categorical variables were compared using the χ2 test. The tests with P value of <0.05 were considered statistically significant. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) version 21.0 software.

Results

I Demographics and Clinical Characteristics

The 156 participants included in the analyse were distributed in 77 (49.35%) men and 79 (50.64%) women. The mean age was 48.97±14.350 years (W: 48.89±14.336 years, M: 48.97±14.358 years, p=0.94) ranging from 19 to 87 years old; 66% of patients were between 30 and 59 years old (Table 1). Nearly half (51.3%) of patients were admitted to isolation wards, and 48.7% received outpatient care. Length of care was 10 days for all patients.

Table 1: Distribution of patients by sex and age groups.

Age (Years)

Women

Men

Total

Number

%

Number

%

Number

%

< 20

20-29

30-39

40-49

50-59

60-69

≥70

Total

1

1,3

2

2,6

3

1,9

6

7,6

4

5,2

10

6,4

13

16,5

15

19,5

28

17,9

25

31,6

23

29,9

48

30,8

16

20,3

11

14,28

27

17,3

13

16,4

15

19,5

28

17,9

5

6,3

7

9,0

12

7,7

79

100,0

77

100,0

156

100,0


The most common symptoms at onset of illness were asthenia (85 [54.5%]), dry cough (82 [52.5%]), headache (57 [36.5%]), myalgia (44 [28.2%]), and fever (31 [19.8%]). Anosmia and ageusia were noted in 27.5% and 30.1% of cases respectively. Less common symptoms were abdominal pain (13.5%), diarrhea (15.4%), nausea (13.5%), and vomiting (5.1%). All clinical data are shown in (Table 2). Hypertension (23,7%), diabetes (25,6%), obesity (21%) and malignancy (1.9%) were the most common coexisting conditions (Table 3). We noted contact with an infected person in 39.74% of cases while preventive measures were not respected in 69.23% of cases.

Table 2: Prevalence of clinical symptoms.

Symptoms

Number

%

asthénia

85

54,5

cough

82

52,5

headache

57

36,5

ageusia

47

30,1

myalgia

44

28,2

anosmia

43

27,5

anorexia

42

26,9

throat irritation

38

24,4

fever

31

19,8

diarrhea

24

15,4

chest pain

21

13,5

nausea

21

13,5

abdominal pain

13

8,3

dyspnea

12

7,7

vomiting

08

5,1

dysphagia

03

1,9

 

Patients Profile

 

Weight (Kg)

79,47±16

BMI (Kg/m2)

27,84±4.27

SBP (mmHg)

117,88±15.191

DBP (mmHg)

75,62±10.25

HR (b/mn)

85±12,064

RR (c/mn)

22,35±7,49

SpO2 (%)

96,29±8,866

BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HR: Heart Rate; RR: Respiration Rates.


Table 3: Prevalence of co-morbidities in order of frequency.

 

Number

%

diabetes

40

25,6

Hypertension

37

23,7

asthma

5

3,2

cancer

3

1,9

Cardiac arrythmia

2

1,3

Ischaemic heart disease

1

0,6


II Laboratory and Radiological Findings

The blood cell count showed leukopenia (10.9%), lymphopenia (46.15%) and thrombocytopenia (10.9%). Other laboratory findings included higher concentration of CRP (67%), hypokalaemia (22.4%) and hepatic cytolysis (18.6%) while increased concentration of D-dimer (7%) and LDH (7%) was relatively less common in all patients (Table 4).

The CT scan was performed in 148 patients, it was normal in 10 patients, showed signs of minimal to moderate COVID pneumonia in 134 patients and severe in 4 patients (Table 5).

Table 4: Summary of the values of biological abnormalities.

Parameters

Mean values

Haemoglobin (g/dl)

12,84±1,485

Leukocytes (103 /mm3)

6174,92±2384,65

lymphocytes (103 /mm3)

1227,3±663,655

platelets (103 /mm3)

235186,29±85272,318

Natremia (mmol/l)

137,9±12,657

kalemie (mmol/l)

3,79±0,589

ESR (mm) (1ere h)

45,83±29,480

CRP (mg/l)

19,29±24,515

LDH (u/l)

325,88±166,485

D-dimers

0,416±0,449

ASAT (u/l)

27,23±17,723

ALAT (u/)

24,23±26,434

Patients Profile

Leukopenia (N %)

17 (10,9)

Lymphopenia (N %)

72 (46,1)

Thrombocytopenia (N %)

17 (10,9)

Hypokalemia (N %)

35 (22,4)

Elevated ESR (N %)

50 (32)

CRP increased (N %)

105 (67)

Hepatic cytolysis (N %)

29 (18,6)

ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; LDH: lactate dehydrogenase; AST: Aspartate transaminase; ALT: Alanine  transaminase.


Table 5: Radiological abnormalities on chest CT.

Extent of lesions

Number

%

<10%

70

44,9

10-25%

44

28,2

25-50%

20

12,8

50- 70%

04

2,6

normal CT

10

6,4

No CT

08

5,1

Total

156

100


On the baseline ECG, the QT interval averaged 398,03 ± 23,635ms; it was high (> 450ms) in two patients justifying the absence of prescription of hydroxychloroquine. No prolong QT interval was observed with the combination of hydroxychloroquine and azithromycin on the third (400,94 ± 23,416ms) and seventh days (403,86 ± 21,690ms) of treatment.

Two patients showed severe symptoms and required oxygen, corticosteroids (80mg of methylprednisolone) and anticoagulation (Enoxaparin in double injection). Cefotaxime (4g/d) was prescribed in four additional patients due to a bacterial infection. We noted a favourable outcome in all of the patients, only one death was noted, it was a diabetic patient with hypertension and coronary heart disease, who presented a respiratory distress on the seventh day of treatment.

Discussion

COVID-19 is a complex pathology which first goes through a short viral entry and then an inflammatory response characterized by a decrease in viremia, a cytokine storm and tissue damage. The clinical spectrum will be complicated by thromboembolic events and bacterial infection [12, 13]. It can vary widely, ranging from asymptomatic infection to respiratory distress [14-16]. Fever, cough, asthenia, myalgia, dyspnea, headache, odynophagia and gastrointestinal signs appear as the main clinical symptoms of the infection, but the semiology can be different from one population to another [17, 18]. Our study described patients infected during the first two months of the epidemic in El Biar hospital in Algiers; their symptoms were dominated by asthenia, cough and otolaryngeal involvement; digestive signs were infrequent and dyspnea was rare.

The mean age of our patients was younger than that reported by Tunisian authors [19]. Only 43% of them were over 50 years old against 75% in Tunisia and 75% in China [19, 20]. The male-female ratio tends to be approximately 1:1. This is lower than that observed in several publications which showed a male predominance, probably related to a higher prevalence of cardiovascular risk factors in men [18, 21-23]. In fact, cardio-metabolic comorbidities, such as hypertension, diabetes and cardiovascular disease affected nearly half of the patients in different published series and some authors even reported that mortality was high among these patients [14, 24, 25]. In our study, this prevalence was around 56%, it was not associated with a high mortality rate. In addition, the frequency of cancerous pathologies noted in our patients (1.9%) was higher than those reported in Chinese studies (0.5% and 0.9%, but did not lead to any death [21, 22].

The most frequent biological abnormality in studies seems to be lymphopenia, it affected nearly half of our patients, as for inflammatory syndrome noted in more than a third of our patients [15, 26, 27]. Hepatic cytolysis was observed in half of the patients in these same studies, it concerned only 18% of our patients. The positive diagnosis of COVID infection in the present study was made mainly by chest CT (95% of cases). The extension of the lesions made it possible to classify the majority of patients in the category of minimal to moderate forms (86%), which joins the figure found by our colleagues at the Rouïba hospital in the east of Algiers (88% ) [28, 29]. The literature shows that the performance of CT is highly variable, its sensitivity approach 90% and its specificity is less than 50% [30-32]. However, a normal CT does not exclude a COVID-19 infection, especially in the first days of illness, which was the case in 6% of our patients [33]. Although Rt-PCR is considered to be the essential element in the diagnosis of COVID-19, it has only been performed in 55 patients due to its unavailability during the first months of the epidemic [34, 35]. It was positive in 63.6% of cases.

The outcome was favourable in 99.4% of patients (one death), we noted a good tolerance of the combination hydroxychloroquine + azithromycin. This efficacy and safety of this treatment has been reported in several publications and thus, the treatment was recommended by several organizations [19, 29, 36-38]. However, some studies dispute these advantages and suggest that these treatments have been associated with increased mortality, probably due to the cardiac toxicity of each molecule, potentiated by their combination [39, 40]. In our report, clinical and electrical monitoring of patients treated with the combination hydroxychloroquine + azithromycin (ECG every two days until the end of treatment) demonstrated the safety of these drugs.

Our study has several limitations. First, chest CT has been used to diagnose COVID-19 in the majority of cases, instead of Rt-PCR (the start of the epidemic in Algeria, an emergency situation, a technical platform not yet ready). Second, our study was observational, of short period (two months) and included only mild clinical forms in the majority of cases; it is therefore difficult to compare our data with those from Chinese and European studies. The finding of a favourable outcome in all of our patients should be interpreted with caution. Finally, a very close surveillance of new infected cases and the analysis of their clinical profile during the following months are the subject of work in progress.

Conclusion

In this single-center series of 156 patients treated during the first two months of the COVID epidemic, the clinical forms were mostly benign and the mortality was exceptional despite the frequency of cardio-metabolic comorbidities. This situation does not seem worrying, compared to that of other countries, it is probably explained by the early drastic measures introduced by the Algerian authorities, such as social distancing imposed by the closure of the country's borders, the closure of schools and the ban on all social, cultural and sporting meetings.

Article Info

Article Type
Research Article
Publication history
Received: Sat 28, Nov 2020
Accepted: Tue 08, Dec 2020
Published: Mon 21, Dec 2020
Copyright
© 2021 Amel Mammeri. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository. All rights reserved.
DOI: 10.31487/j.CDM.2020.01.07

Author Info

Corresponding Author
Amel Mammeri
Department of Internal Medicine, El Biar Hospital, Algiers, Algeria

Figures & Tables

Table 1: Distribution of patients by sex and age groups.

Age (Years)

Women

Men

Total

Number

%

Number

%

Number

%

< 20

20-29

30-39

40-49

50-59

60-69

≥70

Total

1

1,3

2

2,6

3

1,9

6

7,6

4

5,2

10

6,4

13

16,5

15

19,5

28

17,9

25

31,6

23

29,9

48

30,8

16

20,3

11

14,28

27

17,3

13

16,4

15

19,5

28

17,9

5

6,3

7

9,0

12

7,7

79

100,0

77

100,0

156

100,0


Table 2: Prevalence of clinical symptoms.

Symptoms

Number

%

asthénia

85

54,5

cough

82

52,5

headache

57

36,5

ageusia

47

30,1

myalgia

44

28,2

anosmia

43

27,5

anorexia

42

26,9

throat irritation

38

24,4

fever

31

19,8

diarrhea

24

15,4

chest pain

21

13,5

nausea

21

13,5

abdominal pain

13

8,3

dyspnea

12

7,7

vomiting

08

5,1

dysphagia

03

1,9

 

Patients Profile

 

Weight (Kg)

79,47±16

BMI (Kg/m2)

27,84±4.27

SBP (mmHg)

117,88±15.191

DBP (mmHg)

75,62±10.25

HR (b/mn)

85±12,064

RR (c/mn)

22,35±7,49

SpO2 (%)

96,29±8,866

BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HR: Heart Rate; RR: Respiration Rates.


Table 3: Prevalence of co-morbidities in order of frequency.

 

Number

%

diabetes

40

25,6

Hypertension

37

23,7

asthma

5

3,2

cancer

3

1,9

Cardiac arrythmia

2

1,3

Ischaemic heart disease

1

0,6


Table 4: Summary of the values of biological abnormalities.

Parameters

Mean values

Haemoglobin (g/dl)

12,84±1,485

Leukocytes (103 /mm3)

6174,92±2384,65

lymphocytes (103 /mm3)

1227,3±663,655

platelets (103 /mm3)

235186,29±85272,318

Natremia (mmol/l)

137,9±12,657

kalemie (mmol/l)

3,79±0,589

ESR (mm) (1ere h)

45,83±29,480

CRP (mg/l)

19,29±24,515

LDH (u/l)

325,88±166,485

D-dimers

0,416±0,449

ASAT (u/l)

27,23±17,723

ALAT (u/)

24,23±26,434

Patients Profile

Leukopenia (N %)

17 (10,9)

Lymphopenia (N %)

72 (46,1)

Thrombocytopenia (N %)

17 (10,9)

Hypokalemia (N %)

35 (22,4)

Elevated ESR (N %)

50 (32)

CRP increased (N %)

105 (67)

Hepatic cytolysis (N %)

29 (18,6)

ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; LDH: lactate dehydrogenase; AST: Aspartate transaminase; ALT: Alanine  transaminase.


Table 5: Radiological abnormalities on chest CT.

Extent of lesions

Number

%

<10%

70

44,9

10-25%

44

28,2

25-50%

20

12,8

50- 70%

04

2,6

normal CT

10

6,4

No CT

08

5,1

Total

156

100


References

  1. Wuhan Municipal Health Commission (2019) Report of Clustering Pneumonia of Unknown Etiology in Wuhan City.
  2. Zhu N, Zhang D, Wang W, Li X, Yang B et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727-733. [Crossref]
  3. Wu Y, Ho W, Huang Y, Jin DY, Li S et al. (2020) SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet 395: 949-950. [Crossref]
  4. Novel Coronavirus (2019-nCoV) situation reports.
  5. Carte épidémiologique 2020.
  6. The IDF consensus worldwide definition of the metabolic syndrome.
  7. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertension 36: 1953-2041. [Crossref]
  8. Borsini F, Crumb W, Pace S, Ubben D, Wible B et al. (2012) In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother 56: 3261-3270. [Crossref]
  9. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD et al. (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (Covid-19) outbreak - an update on the status. Mil Med Res 7: 11. [Crossref]
  10. Mahsouli A, Grillo M, Amini N et al. (2020) Imagerie thoracique du COVID-19. Louvain Med 139: 360-367.
  11. Plan de preparation et de riposte à la menace de l’infection coronavirus covid-19.
  12. Li H, Liu L, Zhang D, Xu J, Dai H et al. (2020) SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395: 1517-1520. [Crossref]
  13. Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS et al. (2020) Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med 8: 946-949. [Crossref]
  14. Li Q, Guan X, Wu P, Wang X, Zhou L et al. (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med 382: 1199-1207. [Crossref]
  15. Wang D, Hu B, Hu C, Zhu F, Liu X et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA 323: 1061-1069. [Crossref]
  16. Chen N, Zhou M, Dong X, Qu J, Gong F et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507‐513. [Crossref]
  17. Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U et al. (2020) Novel Coronavirus infection (COVID-19) in humans: A scoping review and meta-analysis. J Clin Med 9: 941. [Crossref]
  18. Zhou F, Yu T, Du R, Fan G, Liu Y et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062. [Crossref]
  19. Louhaichi S, Allouche A, Baili H, Jrad S, Radhouani A et al. (2020) Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series. Tunis Med 98: 261-265. [Crossref]
  20. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB et al. (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75: 1730-1741. [Crossref]
  21. Wu C, Chen X, Cai Y, Xia J, Zhou X et al. (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180: 934-943. [Crossref]
  22. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ et al. (2020) Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 382: 1708-1720. [Crossref]
  23. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrin L et al. (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323: 1574-1581. [Crossref]
  24. Chan JFW, Yuan S, Kok KH, To KKW, Chu H et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person‐to‐person transmission: a study of a family cluster. Lancet 395: 514‐523. [Crossref]
  25. Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 323: 1239-1242. [Crossref]
  26. Chen N, Zhou M, Dong X, Qu J, Gong F et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507‐513. [Crossref]
  27. Huang C, Wang Y, Li X, Ren L, Zhao J et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497‐506. [Crossref]
  28. Placais L, Richier Q (2020) COVID-19: clinical, biological and radiological characteristics in adults, infants and pregnant women. An up-to-date review at the heart of the pandemic. Rev Med Interne 41: 308-318. [Crossref]
  29. Ketfi A, Chabati O, Chemali S, Mahjoub M, Gharnaout M et al. (2020) Profil clinique, biologique et radiologique des patients Algériens hospitalisés pour Covid-19: données préliminaires. PAMJ 35: 77.
  30. Ai T, Yang Z, Hou H, Zhan C, Chen C et al. (2020) Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 296: E32-E40. [Crossref]
  31. Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T et al. (2020) Chest CT Features of COVID-19 in Rome, Italy. Radiology 296: E79-E85. [Crossref]
  32. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH et al. (2020) Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology and RSNA. J Thorac Imaging 35: 219-227. [Crossref]
  33. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA et al. (2020) Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology 20: 200463. [Crossref]
  34. Binnicker MJ (2020) Emergence of a novel coronavirus disease (COVID‐19) and the importance of diagnostic testing: why partnership between clinical laboratories, public health agencies, and industry is essential to control the outbreak. Clin Chem 66: 664-666. [Crossref]
  35. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A et al. (2020) Detection of 2019 novel coronavirus (2019‐nCoV) by real‐time RT‐PCR. Euro Surveill 25: 2000045. [Crossref]
  36. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56: 105949. [Crossref]
  37. Gao J, Tian Z, Yang X (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14: 72-73. [Crossref]
  38. Audio transcript of the news briefing held by the State Council of China (2020) The National Health Commission of the People's Republic of China.
  39. Mehra MR, Desai S, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. [Crossref]
  40. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer Smadja N et al. (2020) Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis. Clin Microbiol Infect. [Crossref]